-
Something wrong with this record ?
Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma
J. Kersting, A. Ranft, V. Bhadri, B. Brichard, S. Collaud, S. Cyprová, H. Eich, T. Ek, H. Gelderblom, J. Hardes, L. Haveman, W. Hartmann, P. Hauser, P. Heesen, H. Jürgens, J. Kanerva, T. Kühne, A. Raciborska, J. Rascon, V. Rechl, A. Streitbürger,...
Status not-indexed Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2016
PubMed Central
from 2016
Europe PubMed Central
from 2016
Open Access Digital Library
from 2016-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2016
- Publication type
- Journal Article MeSH
PURPOSE: Radiation therapy (RT) is an integral part of Ewing sarcoma (EwS) therapy. The Ewing 2008 protocol recommended RT doses ranging from 45 to 54 Gy. However, some patients received other doses of RT. We analyzed the effect of different RT doses on event-free survival (EFS) and overall survival (OS) in patients with EwS. METHODS AND MATERIALS: The Ewing 2008 database included 528 RT-admitted patients with nonmetastatic EwS. Recommended multimodal therapy consisted of multiagent chemotherapy and local treatment consisting of surgery (S&RT group) and/or RT (RT group). EFS and OS were analyzed with uni- and multivariable Cox regression models including known prognostic factors such as age, sex, tumor volume, surgical margins, and histologic response. RESULTS: S&RT was performed in 332 patients (62.9%), and 145 patients (27.5%) received definitive RT. Standard dose ≤ 53 Gy (d1) was admitted in 57.8%, high dose of 54 to 58 Gy (d2) in 35.5%, and very high dose ≥ 59 Gy (d3) in 6.6% of patients. In the RT group, RT dose was d1 in 11.7%, d2 in 44.1%, and d3 in 44.1% of patients. Three-year EFS in the S&RT group was 76.6% for d1, 73.7% for d2, and 68.2% for d3 (P = .42) and in the RT group 52.9%, 62.5%, and 70.3% (P = .63), respectively. Multivariable Cox regression revealed age ≥ 15 years (hazard ratio [HR], 2.68; 95% confidence interval [CI], 1.63-4.38) and nonradical margins (HR, 1.76; 95% CI, 1.05-2.93) for the S&RT group (sex, P = .96; histologic response, P = .07; tumor volume, P = .50; dose, P = .10) and large tumor volume (HR, 2.20; 95% CI, 1.21-4.0) for the RT group as independent factors (dose, P = .15; age, P = .08; sex, P = .40). CONCLUSIONS: In the combined local therapy modality group, treatment with higher RT dose had an effect on EFS, whereas higher dose of radiation when treated with definitive RT was associated with an increased OS. Indications for selection biases for dosage were found. Upcoming trials will assess the value of different RT doses in a randomized manner to control for potential selection bias.
2nd Department of Pediatrics Semmelweis University Budapest Hungary
Charles University Motol Children ́s Hospital Prague Czech Republic
Clinic of Orthopedics University Hospital Essen West German Cancer Centre Essen Germany
Department of Medical Oncology Leiden University Medical Center Leiden The Netherlands
Department of Oncology Haematology University Children ́s Hospital Basel Basel Switzerland
Department of Solid Tumors Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
German Cancer Consortium Partnersite Essen Essen Germany
Institute of Clinical Sciences Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
St Josef's Hospital Bochum University Hospital Bochum Germany
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009467
- 003
- CZ-PrNML
- 005
- 20240223083117.0
- 007
- ta
- 008
- 230707s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.adro.2023.101269 $2 doi
- 035 __
- $a (PubMed)37334316
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kersting, Josephine $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite Essen, Essen, Germany
- 245 10
- $a Effect of Radiotherapy Dose on Outcome in Nonmetastatic Ewing Sarcoma / $c J. Kersting, A. Ranft, V. Bhadri, B. Brichard, S. Collaud, S. Cyprová, H. Eich, T. Ek, H. Gelderblom, J. Hardes, L. Haveman, W. Hartmann, P. Hauser, P. Heesen, H. Jürgens, J. Kanerva, T. Kühne, A. Raciborska, J. Rascon, V. Rechl, A. Streitbürger, B. Timmermann, Y. Uhlenbruch, U. Dirksen
- 520 9_
- $a PURPOSE: Radiation therapy (RT) is an integral part of Ewing sarcoma (EwS) therapy. The Ewing 2008 protocol recommended RT doses ranging from 45 to 54 Gy. However, some patients received other doses of RT. We analyzed the effect of different RT doses on event-free survival (EFS) and overall survival (OS) in patients with EwS. METHODS AND MATERIALS: The Ewing 2008 database included 528 RT-admitted patients with nonmetastatic EwS. Recommended multimodal therapy consisted of multiagent chemotherapy and local treatment consisting of surgery (S&RT group) and/or RT (RT group). EFS and OS were analyzed with uni- and multivariable Cox regression models including known prognostic factors such as age, sex, tumor volume, surgical margins, and histologic response. RESULTS: S&RT was performed in 332 patients (62.9%), and 145 patients (27.5%) received definitive RT. Standard dose ≤ 53 Gy (d1) was admitted in 57.8%, high dose of 54 to 58 Gy (d2) in 35.5%, and very high dose ≥ 59 Gy (d3) in 6.6% of patients. In the RT group, RT dose was d1 in 11.7%, d2 in 44.1%, and d3 in 44.1% of patients. Three-year EFS in the S&RT group was 76.6% for d1, 73.7% for d2, and 68.2% for d3 (P = .42) and in the RT group 52.9%, 62.5%, and 70.3% (P = .63), respectively. Multivariable Cox regression revealed age ≥ 15 years (hazard ratio [HR], 2.68; 95% confidence interval [CI], 1.63-4.38) and nonradical margins (HR, 1.76; 95% CI, 1.05-2.93) for the S&RT group (sex, P = .96; histologic response, P = .07; tumor volume, P = .50; dose, P = .10) and large tumor volume (HR, 2.20; 95% CI, 1.21-4.0) for the RT group as independent factors (dose, P = .15; age, P = .08; sex, P = .40). CONCLUSIONS: In the combined local therapy modality group, treatment with higher RT dose had an effect on EFS, whereas higher dose of radiation when treated with definitive RT was associated with an increased OS. Indications for selection biases for dosage were found. Upcoming trials will assess the value of different RT doses in a randomized manner to control for potential selection bias.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ranft, Andreas $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite Essen, Essen, Germany
- 700 1_
- $a Bhadri, Vivek $u Chris O ́ Brien Lifehouse, Camperdown, Australia Faculty of Medicine and Health, University of Sydney, Camperdown, Australia
- 700 1_
- $a Brichard, Bénédicte $u Cliniques Universitaires Saint Luc, Department of Pediatric Haematology and Oncology, Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Collaud, Stéphane $u Department of Thoracic Surgery, Lung Clinic, Cologne-Merheim City Hospital, University of Witten Herdecke, Cologne, Germany
- 700 1_
- $a Cyprová, Soňa $u Charles University, Motol Children ́s Hospital, Prague, Czech Republic $7 xx0314248
- 700 1_
- $a Eich, Hans $u Radiotherapy and Radiooncology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany
- 700 1_
- $a Ek, Torben $u Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- 700 1_
- $a Gelderblom, Hans $u Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Hardes, Jendrik $u German Cancer Consortium, Partnersite Essen, Essen, Germany $u Clinic of Orthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany
- 700 1_
- $a Haveman, Lianne $u Department of Solid Tumors, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Hartmann, Wolfgang $u Gerhard Domagk Institute for Pathology, University Hospital Muenster, West German Cancer Center Network, Muenster, Germany
- 700 1_
- $a Hauser, Peter $u Second Department of Pediatrics, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Heesen, Philip $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Jürgens, Heribert $u Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, West German Cancer Center Network, Münster, Germany
- 700 1_
- $a Kanerva, Jukka $u HUS Helsinki University Hospital, New Children ́s Hospital, Div. Hematology and Stem Cell Transplantation, Helsinki, Finland
- 700 1_
- $a Kühne, Thomas $u Department of Oncology/Haematology, University Children ́s Hospital Basel, Basel, Switzerland
- 700 1_
- $a Raciborska, Anna $u Department of Oncology and Surgical Oncology for Children and Youth, Mother and Child Institute, Warsaw, Poland
- 700 1_
- $a Rascon, Jelena $u Center for Pediatric Oncology and Hematology, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania
- 700 1_
- $a Rechl, Victor $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- 700 1_
- $a Streitbürger, Arne $u German Cancer Consortium, Partnersite Essen, Essen, Germany $u Clinic of Orthopedics, University Hospital Essen, West German Cancer Centre, Essen, Germany
- 700 1_
- $a Timmermann, Beate $u German Cancer Consortium, Partnersite Essen, Essen, Germany $u Clinic for Particle Therapy, West German Proton Beam Centre, University Hospital Essen, West German Cancer Centre, German Cancer Research Centre (DKTK), Essen, Germany
- 700 1_
- $a Uhlenbruch, Yasmine $u St. Josef's Hospital Bochum, University Hospital, Bochum, Germany
- 700 1_
- $a Dirksen, Uta $u Pediatrics III, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany $u German Cancer Consortium, Partnersite Essen, Essen, Germany
- 773 0_
- $w MED00211259 $t Advances in radiation oncology $x 2452-1094 $g Roč. 8, č. 4 (2023), s. 101269
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37334316 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20240223083111 $b ABA008
- 999 __
- $a ok $b bmc $g 1958382 $s 1195731
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 8 $c 4 $d 101269 $e 20230614 $i 2452-1094 $m Advances in radiation oncology $n Adv Radiat Oncol $x MED00211259
- LZP __
- $a Pubmed-20230707
